Document is current
Any future updates will be listed below
-
Authors
Qiu, Yan https://orcid.org/0000-0001-9704-7697
Cattaneo, Monica
Maciag, Anna
Puca, Annibale A.
Madeddu, Paolo
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/W017385/1, MR/W017385/1, MR/W017385/1, MR/W017385/1, MR/W017385/1)
the Italian Ministry of Health, Ricerca Corrente, through IRCCS MultiMedica
- License Information
-
More Information
Article History
Received: 28 January 2025
Revised: 15 August 2025
Accepted: 27 August 2025
First Online: 29 September 2025
Competing interests
: A.A.P. have shares of LGV1 Inc. and has filed a patent. All the other authors declare that there is no conflict of interest.
: All animal procedures conformed to the guidelines from Directive 2010/63/EU of the European Parliament on protecting animals used for scientific purposes and were approved by the University of Bristol and the British Home Office (PPL: PP1377882). Human primary dermal fibroblast cell lines were obtained from the Progeria Research Foundation (PRF) Cell and Tissue Bank. The HGPS cell lines included: HGADFN167, HGADFN169, and HGADFN367. The control cell lines were: HGMDFN718, HGFDFN168, HGMDFN368, HGFDFN369, and HGMDFN717.
